aid: qnovia
name: Qnovia
description: >-
  Qnovia, Inc. is a clinical-stage pharmaceutical and drug-device company developing inhaled
  therapeutics built on its proprietary RespiRx aseptically pre-filled, portable vibrating-mesh
  nebulizer platform. Its lead asset, the RespiRx Nicotine Inhaler (QN-01), is a prescription
  smoking-cessation therapy that cleared FDA IND review and has dosed patients in a U.S. Phase 1
  study; a cognitive behavioral therapy (CBT) program is advancing toward a second IND. The device
  is Bluetooth Low Energy connected and pairs with Neblit AI, a cloud-connected companion app and
  machine-learning platform that tracks dose events and delivers behavioral interventions, which the
  company positions as a digital therapeutic layer over the pharmacotherapy. Founded in 2018 as
  Respira Technologies and rebranded to Qnovia in 2022, the company is led by founder and CEO Mario
  Danek, operates R&D and manufacturing in Newport Beach/Irvine, California and an R&D facility in
  Richmond, Virginia, and has raised roughly $50 million to date. Qnovia publishes no public API,
  developer portal, SDK, or machine-readable contract; its corporate site is a client-rendered
  single-page application whose only HTTP API is a private backend serving its own contact, careers
  and investor-portal forms.
url: https://raw.githubusercontent.com/api-evangelist/qnovia/refs/heads/main/apis.yml
deliveryModel:
  model: saas
  open_source: false
  commercial: true
  callable_host: false
  label: Hosted service · you call their endpoint
  confidence: medium
  source:
  - pricing
  generated: '2026-08-28'
  method: derived
image: https://qnovia.com/favicon.png
x-type: company
x-source: harvest:secondary-market
specificationVersion: '0.20'
created: '2026-08-26'
modified: '2026-08-26'
tags:
- Company
- Pharmaceuticals
- Medical Devices
- Drug Delivery
- Digital Health
- Digital Therapeutics
- Respiratory
- Smoking Cessation
- Connected Devices
- Clinical Trials
- Artificial Intelligence
- Health
apis: []
maintainers:
- FN: Kin Lane
  email: kin@apievangelist.com
- FN: APIs.json
  email: info@apis.io
common:
- type: Website
  url: https://qnovia.com/
- type: About
  url: https://qnovia.com/about/story
- type: Product
  url: https://qnovia.com/product
- type: Technology
  url: https://qnovia.com/technology
- type: Pipeline
  url: https://qnovia.com/pipeline
- type: Team
  url: https://qnovia.com/team
- type: News
  url: https://qnovia.com/news
- type: Careers
  url: https://qnovia.com/careers
- type: Support
  url: https://qnovia.com/contact
- type: Investors
  url: https://qnovia.com/investors
- type: TermsOfService
  url: https://qnovia.com/terms
- type: PrivacyPolicy
  url: https://qnovia.com/privacy
- type: SecondaryMarket
  url: https://forgeglobal.com/qnovia_stock/
- type: DomainSecurity
  url: security/qnovia-domain-security.yml
- type: LLMsTxt
  url: llms/qnovia-llms.txt
- type: Packages
  url: packages/qnovia-packages.yml
- type: Plans
  url: plans/qnovia-plans-pricing.yml
- type: RateLimits
  url: rate-limits/qnovia-rate-limits.yml
x-enrichment:
  date: '2026-08-26'
  status: minimal
  artifacts_added: 6
  pass: local-v1
x-coverage:
  state: none
  reason: no-developer-program
  detail: >-
    Qnovia is a clinical-stage drug-device company that does write software — BLE device firmware and
    the cloud-connected Neblit AI companion app — but ships none of it to third parties: the
    qnovia.com route table extracted from its own JavaScript bundle has no developer, API or docs
    route, and the only HTTP API on the host is the private /api/ backend behind its contact and
    investor-portal forms, which answered 401 "Not authenticated".
  evidence:
  - url: https://qnovia.com/api/investors/me
    status: 401
  - url: https://qnovia.com/openapi.json
    status: 200
  - url: https://qnovia.com/.well-known/agent-card.json
    status: 200
  - url: https://api.github.com/orgs/qnovia
    status: 404
  checked: '2026-08-26'